GTx to Host Key Opinion Leader Luncheon on the Topic of Stress Urinary Incontinence on September 28th in New York City

MEMPHIS, Tenn.--(BUSINESS WIRE)--GTx, Inc. (Nasdaq: GTXI) today announced that it will be hosting and simultaneously webcasting a Key Opinion Leader (KOL) luncheon meeting on the topic of Stress Urinary Incontinence (SUI) on Thursday, September 28^th in New York City beginning at 12:00 p.m. EDT.

The meeting will feature presentations by key opinion leaders Roger Dmochowski, MD (Vanderbilt University), William Evans, PhD (Duke University), and Diane Newman, DNP, FAAN (University of Pennsylvania) who will discuss the current treatment landscape and unmet medical need for patients with SUI. The KOLs will be available to answer questions at the conclusion of the event.

GTx's management team will also provide an overview of the Company’s ongoing clinical development program with enobosarm (GTx-024), a novel small molecule candidate to treat stress urinary incontinence. Enobosarm is an orally-administered selective androgen receptor modulator (SARM), which is currently in Phase 2 clinical trial development for the treatment of SUI in postmenopausal women. The company released top-line clinical results from its ongoing Phase 2 proof-of-concept clinical trial of enobosarm to treat SUI on September 13, 2017.

The in-person luncheon meeting is intended for institutional investors, sell-side analysts, investment bankers, and business development professionals only. Please RSVP in advance if you plan to attend in person, as space is limited. A simultaneous webcast of the luncheon meeting will be accessible from the GTx website at http://www.gtxinc.com. An archived replay of the presentation will be available on GTx’s website. Please connect to the website prior to the start of the luncheon meeting to ensure adequate time for any software downloads that may be necessary to listen to the webcast.

About GTx
GTx, Inc., headquartered in Memphis, Tennessee, is a biopharmaceutical company dedicated to the discovery, development and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions.